eskisehir termal otel ankara evden eve nakliyat Antika mobilya alanlar

Moderna says RSV vaccine is 84% ​​effective in preventing disease in older adults

Moderna's phase three RSV trial found to be 83.7% effective in older adults

Modern said on Tuesday that its vaccine targeting respiratory syncytial virus is effective in preventing the disease in the elderly.

The vaccine was 83.7% effective in preventing lower respiratory tract disease, defined as two or more symptoms, in people age 60 and older, according to the Boston biotech company. It was 82.4% effective in preventing lower respiratory tract disease with three or more symptoms.

No safety issues were identified during the clinical trial of the vaccine, according to Moderna. Safety and efficacy data from the trial will be published in a peer-reviewed journal, according to the company. The clinical trial recruited around 37,000 people in 22 countries.

Moderna said it plans to file for Food and Drug Administration approval in the first half of this year. There is currently no FDA-approved vaccine for RSV.

A woman receives a booster dose of the Moderna coronavirus disease (COVID-19) vaccine at a vaccination center in Antwerp, Belgium, February 1, 2022.

Johanna Geron | Reuters

Moderna’s stock rose nearly 7% in extended trading.

RSV infections kill between 6,000 and 10,000 elderly people each year and lead to 60,000 to 120,000 hospitalizations, according to the Centers for Disease Control and Prevention.

The United States suffered an unusually severe RSV season last fall among children and the elderly as the public largely ceased practicing public health measures implemented in response to the Covid-19 pandemic, such as as masking and social distancing.

Moderna’s RSV vaccine uses the same messenger RNA technology as the company’s successful Covid vaccines. The Covid vaccine has made Moderna a global name and generated windfall profits, but it remains the company’s only commercially available product and demand is waning.

The Boston biotech company faces increasing pressure to demonstrate that other products in its pipeline will successfully come to market. Morgan Stanley estimates the market for an adult RSV vaccine to be between $7 billion and $10 billion.

CNBC Health and Science

Read CNBC’s latest global health coverage:

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Bolu escort gümüshane escort istanbul escort Kamagra Levitra Novagra Geciktirici